Literature DB >> 10673245

Antileukotriene therapy. Future directions.

S T Holgate1, A P Sampson.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10673245     DOI: 10.1164/ajrccm.161.supplement_1.ltta-29

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  6 in total

Review 1.  Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman; Jennifer M Colombo; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

Review 2.  Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age.

Authors:  Richard B R Muijsers; Stuart Noble
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population.

Authors:  Seung-Hyun Kim; Jeong-Hee Choi; J W Holloway; Chang-Hee Suh; Dong-Ho Nahm; Eun-Ho Ha; Choon-Sik Park; Hae-Sim Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

5.  Eosinophilic inflammation in allergic asthma.

Authors:  Samantha S Possa; Edna A Leick; Carla M Prado; Mílton A Martins; Iolanda F L C Tibério
Journal:  Front Pharmacol       Date:  2013-04-17       Impact factor: 5.810

6.  New drugs targeting Th2 lymphocytes in asthma.

Authors:  Gaetano Caramori; David Groneberg; Kazuhiro Ito; Paolo Casolari; Ian M Adcock; Alberto Papi
Journal:  J Occup Med Toxicol       Date:  2008-02-27       Impact factor: 2.646

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.